New, super-sensitive blood tests can spot tiny amounts of PSA that older tests miss, letting doctors find cancer coming back much sooner—sometimes years before it would have been noticed before.
Scientific Claim
Ultrasensitive PSA assays with a limit of quantitation below 10 ng/L can detect biochemical recurrence of prostate cancer months to years earlier than conventional assays, enabling earlier clinical intervention in men who would otherwise be classified as having undetectable PSA.
Original Statement
“Until 2021, the European Association of Urology recommended a PSA threshold > 0.2 ng/mL (>200 ng/L) to diagnose PSAR. But, recently, EAU guidelines abandoned the threshold. ... uPSAs can measure PSA nadir for these patients. These assays quantify extremely low PSA values.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The claim describes a technical capability of assays, which is directly supported by the 36 studies reporting assay performance. It does not overstate causation.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Prospective Cohort StudyLevel 2aIn EvidenceThe time advantage in detecting recurrence using ultrasensitive vs. conventional PSA assays and its impact on clinical outcomes.
The time advantage in detecting recurrence using ultrasensitive vs. conventional PSA assays and its impact on clinical outcomes.
What This Would Prove
The time advantage in detecting recurrence using ultrasensitive vs. conventional PSA assays and its impact on clinical outcomes.
Ideal Study Design
A prospective cohort of 1,000 men after radical prostatectomy, with paired monthly PSA measurements using both conventional (LLD 0.1 ng/mL) and fifth-generation ultrasensitive (LLD 0.001 ng/mL) assays, recording time to detection of recurrence and time to initiation of SRT, with imaging confirmation.
Limitation: Does not prove that earlier detection improves survival—only that detection occurs earlier.
Cross-Sectional StudyLevel 3In EvidenceThe proportion of men with recurrence detected only by ultrasensitive assays at PSA levels below conventional thresholds.
The proportion of men with recurrence detected only by ultrasensitive assays at PSA levels below conventional thresholds.
What This Would Prove
The proportion of men with recurrence detected only by ultrasensitive assays at PSA levels below conventional thresholds.
Ideal Study Design
A cross-sectional analysis of 500 men with 'undetectable' PSA by conventional assay (<0.1 ng/mL) but rising PSA by ultrasensitive assay, with PSMA PET/CT to confirm presence of residual disease.
Limitation: Cannot assess long-term outcomes or causality.
In Vitro Assay Validation StudyLevel 5In EvidenceAnalytical sensitivity and precision of ultrasensitive assays compared to conventional methods.
Analytical sensitivity and precision of ultrasensitive assays compared to conventional methods.
What This Would Prove
Analytical sensitivity and precision of ultrasensitive assays compared to conventional methods.
Ideal Study Design
A laboratory validation study comparing 6 ultrasensitive PSA assays (LLD <1 ng/L) and 3 conventional assays using WHO reference materials, measuring precision (CV%), linearity, and recovery across 0.001–10 ng/L range.
Limitation: Does not reflect clinical performance or patient outcomes.
Evidence from Studies
Supporting (1)
This study shows that using super-sensitive blood tests to spot tiny amounts of PSA after prostate surgery can warn doctors of cancer coming back much earlier than old tests could — and catching it early helps patients live longer.